Loading this company
Alamar Biosciences, Inc.
ALMRPrices in USD
TickerWorth ScoreD42/100
What we think
Priced above our one model’s value of $8.91.
Price
$26.30USD up +$1.02 (+4.03%)
Quoted · Prices are delayed.
Showing the last price we hold for this listing, recorded 2026-10-19 15:54 UTC (4 hours ago).
Why did it move today?
Nothing we can cite explains today’s move for this company.
Is it cheap?
One model only, on today’s numbers
$8.91
What the price needs: revenue growth of more than 25%/yr for 5 years, more than our model can justify (it assumes 16.6%).
Led by peer multiples (P/E, EV/EBITDA, P/S) · Fast grower
Price $26.30Priced · Prices are delayed.
Is it a good business?
- Valuation50 out of 100
- Growth100 out of 100
- Financial health100 out of 100
- Past performance50 out of 100
Bull, base, bear
Our forward range over 12 months is part of Pro. See plans
The street
Analysts’ mean target
$35.40 across 5 analysts
The high and low of the analyst range is part of Pro. See plans
What does it do?
Alamar Biosciences, Inc., a proteomics company, develops a proteomic liquid biopsy platform and sells instruments, consumables, and services to early detection of diseases. The company develops NULISA technology, a proteomics platform that detects and quantifies protein biomarkers. It operates in the Medical Devices industry (Healthcare sector), headquartered in United States. The company employs roughly 286 people.
Key stats
52-week range$18.85–$39.61
- Open
- $25.29
- Day high
- $26.35
- Day low
- $25.28
- Previous close
- $25.28
- Volume
- 104,849 · 0.23× avg
- Average volume
- 463,189
- Market cap
- $1,825,029,760.00
- P/E (TTM)
- —
- Earnings per share
- −$1.20
- Beta
- —
Prices are delayed. The feed does not say when these figures were taken.
What’s the latest?
- Changed leadership or its board
- Reported quarterly or annual results
- Disclosed another material event
- Reported quarterly or annual results
- Amended its charter or bylaws
Top news
No recent headlines we can cite for this company.
Insider trades
The 90-day buying-and-selling read is part of Pro. See plans
- Brottem John L.Grant / award · —
- RAGUSA ROBERT PGrant / award · —
- Qiming Corporate GP VI, Ltd.
Not investment advice. TickerWorth Score is a model output.